Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06007677 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 20 to 22
    v9
  2. Study sites: 15 to 20v8
  3. Study sites: 14 to 15v7
  4. Study sites: 13 to 14v6
  5. Primary and study completion dates: Aug 2030 to Mar 2031v5 Show 4 more changesShow less
    • Trial status: Enrolling by Invitation to Recruiting
    • Study sites: 11 to 13
    • Eligibility criteria expanded, about 24 words
    • Study arms: 2 to 4
Show 3 earlier versionsHide 3 earlier versions
  1. Study sites: 3 to 11v4
  2. Primary and study completion dates: Oct 2029 to Aug 2030
    • Study sites: 1 to 3
    • Secondary endpoints revised (10)
    v3
  3. Trial status: Not Yet Recruiting to Enrolling by Invitation
    • Study sites: 0 to 1
    • Start date changed from estimate of Sep 2023 to Sep 26, 2023
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this trial is to enable the collection of information about long-term safety and clinical activity of STAR-0215 in participants with hereditary angioedema (HAE). Participants will receive repeat doses of STAR-0215 for up to 5 years.
Trial Details
NCT Number NCT06007677
Lead Sponsor Astria Therapeutics, Inc.
Conditions
(from sponsor)		 Hereditary Angioedema
Related terms Angioedema, Angioedemas, Hereditary
Enrollment 56 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov